<DOC>
	<DOCNO>NCT00722098</DOCNO>
	<brief_summary>The purpose study determine whether combination chemotherapy ( Cyclophosphamide ) CD34-DC vaccine result improved rate clinical response stage IV melanoma patient .</brief_summary>
	<brief_title>Comparison Study Dendritic Cell Vaccine With Without Cyclophosphamide Treat Stage IV Melanoma Patients</brief_title>
	<detailed_description>Vaccination patient metastatic melanoma use ex vivo generate dendritic cell ( DCs ) load tumor-associated antigen ( ) show induce tumor-specific immunity melanoma antigen measure vitro assay , case , tumor regression . At present time , number record patient metastatic melanoma treat DC vaccination small predict certainty future overall therapeutic value DC vaccination management patient metastatic melanoma . The purpose study gather data feasibility efficacy novel combination therapy CPA DC vaccine outline protocol treat metastatic melanoma .</detailed_description>
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<criteria>1 . Biopsyproven metastatic melanoma , Stages M1a , M1b , M1c 2 . HLAA*0201 phenotype 3 . Age : 2175 year 4 . ECOG performance status 01 5 . Measurable metastatic melanoma lesion physical examination radiograph scan . 6 . Adequate marrow function : White count ≥ 4,000/microliter : Subjects recently complete chemotherapy allow study entry White count ≥ 3,500/microliter Hemoglobin ≥ 10.0 gm : Subjects recently complete chemotherapy allow study entry Hemoglobin ≥ 9.0 gm . Platelets ≥ 100,000/microliter 7 . Adequate hepatic function : Bilirubin ≤ 1.5/mg/dL Alkaline phosphatase ≤ 5 time upper limit normal SGOT ≤ 5 time upper limit normal SGPT ≤ 5 time upper limit normal 8 . Adequate renal function : Serum creatinine ≤ 1.5/mg/dL 9 . No active CNS metastatic disease screening . Patients history CNS melanoma lesion must lesion resect surgery and/or gamma knife irradiation least 3 month prior study entry . The total number CNS lesion diagnosis exceed 3 . 10 . Written inform consent 1 . Patients receive &gt; 8 cycle cytotoxic chemotherapy metastatic melanoma 2 . Patients receive chemotherapy &lt; 4 week begin trial 3 . Patients receive interferon alpha ( IFNα2b ) sargramostim ( GMCSF ) &lt; 4 week begin trial 4 . Patients receive highdose interleukin2 ( IL2 ) &lt; 4 week begin trial 5 . Patients diagnose 3 CNS melanoma lesion . 6 . Patients diagnose 5 hepatic metastasis hepatic metastasis &gt; 5 cm . 7 . Baseline serum LDH &gt; 1.1 time upper limit normal 8 . Patients HIV+ ( HIV patient often profoundly immunodeficient viral infection additional parameter interfere evaluation DC induce immune response melanoma patient . Furthermore , safety collect DCs , load antigen reinfusing cell HIV+ patient yet determine . ) 9 . Pregnancy ( Pregnancy associate considerable immunosuppression 70 additional parameter interfere evaluation DC induce immune response melanoma patient . In addition , safety tolerability cell bodyloaded DC give subcutaneously entirely unknown . ) 10 . Patients receive corticosteroid immunosuppressive agent &lt; 4 week begin trial 11 . Patients active asthma and/or treatment asthma 12 . Patients angina pectoris 13 . Patients congestive heart failure 14 . Patients history autoimmune disease include lupus erythematosus , rheumatoid arthritis thyroiditis 15 . Patients active infection include viral hepatitis 16 . Patients history neoplastic disease melanoma &lt; 5 year prior entry trial except patient carcinomas situ cervix basal/squamous cell carcinoma skin . Patients two type cancer melanoma include .</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>July 2013</verification_date>
	<keyword>Melanoma</keyword>
	<keyword>Dendritic Cell</keyword>
	<keyword>Vaccine</keyword>
	<keyword>Immunotherapy</keyword>
	<keyword>Cyclophosphamide</keyword>
</DOC>